2 years ago
JNJ
AnalystsAsad HaiderAsad Haider's Stock Forecasts
AnalystsAsad Haider
Sectors:
Industries:
Analyst Ranking
Top 35%
#1957 out of 5550 analysts
Average Return
+26.41%
Win Rate
71%5 out of 7
Risk vs Reward
Poor
Good
Asad Haider's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Royalty Pharma PLCRPRX | +65.02% | $35.28 | $58.22 | 2025-09-30 - 2026-09-29 | Strong Buy |
Johnson & JohnsonJNJ | +59.83% | $150.97 | $241.30 | 2025-04-09 - 2026-04-08 | Strong Buy |
Johnson & JohnsonJNJ | +34.23% | $191.08 | $256.48 | 2025-10-09 - 2026-10-08 | Strong Buy |
Johnson & JohnsonJNJ | +32.38% | $206.37 | $273.20 | 2025-12-19 - 2026-10-30 | Strong Buy |
Eli Lilly & CoLLY | +28.21% | $726.24 | $931.09 | 2025-04-08 - 2026-04-07 | Strong Buy |
Asad Haider Analyst Color
Get additional color on Asad Haider's coverage of popular stocks
2 years ago
LLY
2 years ago
PFE
Asad Haider's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Abbvie IncABBV | 2 | Hold | $294.00 | -0.30% | Maintains | 8 days ago |
Biontech SeBNTX | 2 | Strong Buy | $142.00 | +61.05% | Upgrades | 10 months ago |
Johnson & JohnsonJNJ | 3 | Strong Buy | $240.00 | -12.15% | Maintains | 10 months ago |
Newamsterdam Pharma Co NvNAMS | 2 | Hold | $37.00 | +84.45% | Maintains | a year ago |
Bristol Myers Squibb CoBMY | 2 | Hold | $57.00 | -8.77% | Maintains | a year ago |
Innoviva IncINVA | 1 | Strong Sell | $17.00 | N/A | Initiates Coverage On | a year ago |
Royalty Pharma PLCRPRX | 1 | Strong Buy | $42.00 | N/A | Initiates Coverage On | a year ago |
Vaxcyte IncPCVX | 1 | Hold | $38.00 | N/A | Initiates Coverage On | a year ago |
Eli Lilly & CoLLY | 1 | Strong Buy | $888.00 | N/A | Upgrades | 2 years ago |
Pfizer IncPFE | 1 | Hold | $25.00 | N/A | Downgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.